Stay updated on Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial

Sign up to get notified when there's something new on the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Fallopian tube cancer was added to the study conditions, and the Genetic and Rare Diseases Information Center resource was added.
    Difference
    0.1%
    Check dated 2026-02-18T07:37:44.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the prior government-funding lapse notice (Revision: v3.4.1); no study data, eligibility criteria, or core page content were changed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-02-11T11:00:19.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A new site-wide notice has been added about the lapse in government funding and the NIH Clinical Center's operating status. The page revision has been updated from v3.4.0 to v3.4.1.
    Difference
    0.3%
    Check dated 2026-02-04T06:21:55.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The page now shows a glossary toggle and includes updated Study Record Dates such as Results First Posted and Certification/Extension First Posted, along with a new Revision/Version label.
    Difference
    0.3%
    Check dated 2026-01-28T04:24:11.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Results posted for PICCOLO (NCT05041257): the page now includes posted results and related details for the Phase 2, single-arm Mirvetuximab Soravtansine study in FRα-positive ovarian, peritoneal, and fallopian tube cancers. The locations list has been updated to 35 sites worldwide with corresponding names and IDs, and key identifiers (EudraCT 2021-003592-34) plus study start and completion dates are displayed.
    Difference
    9%
    Check dated 2026-01-14T02:41:59.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    The Locations section was expanded to include numerous US states and international sites (e.g., New South Wales, South Australia, Victoria, Ontario, Quebec, Madrid), while the HHS Vulnerability Disclosure link was removed.
    Difference
    2%
    Check dated 2025-12-23T13:31:27.000Z thumbnail image

Stay in the know with updates to Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page.